- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07857070
Newborn Brain Assessment - CergenX Wave (NBT)
Determining Grade of Neonatal Encephalopathy - Agreement Between the Modified Sarnat Examination and Automated AI Assessment of Newborn Brain Function Using Wave Software
In this study we want to assess how a newly developed software device called CergenX Wave compares to the modified Sarnat examination, performed by the neonatology team . The Wave software algorithm (which is a set of rules used by the computer) analyses EEG activity, using four electrodes placed on the neonate's scalp.
A portable EEG machine records the EEG activity and a tablet will send this information to the cloud where the device analyses the data, as shown in the figure below. The EEG activity the Wave device evaluates will not be available to either the research or clinical team during the investigation but once the recording is completed the device will display a code on screen for the research team to confirm completion.
The results will not be visible to either the researchers or the clinical team therefore will not in any way influence the care of the neonate. This is a regulated observational investigation to compare how the software performs against the current standard of care, a standardised neurological examination.
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Type d'étude
Inscription (Estimé)
Contacts et emplacements
Coordonnées de l'étude
- Nom: Brian Walsh, Neonatologist
- Numéro de téléphone: +353214920525
- E-mail: brianhenry.walsh@ucc.ie
Lieux d'étude
-
-
Cork
-
Cork, Cork, Irlande
- Recrutement
- Cork University Maternity Hospital
-
Contact:
- Aisling Fanning
- Numéro de téléphone: +353214920525
- E-mail: aisling.fanning1@hse.ie
-
-
-
-
Texas
-
Dallas, Texas, États-Unis, 75235
- Pas encore de recrutement
- University of Texas Southwestern Medical Center
-
Contact:
- Lina Chalak
- Numéro de téléphone: 214-648-3060
- E-mail: Lina.Chalak@UTSouthwestern.edu
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
Infants at high-risk of Neonatal Encephalopathy
La description
Inclusion Criteria:
-
Infants born at ≥36+0 weeks gestational age
-
Informed consent obtained AND
-
A pH of ≤7.0 or base deficit ≥16 (on cord or 1st infant blood gas at < 1 hour of life) OR
-
a) A pH of 7.01-7.15 or base deficit of 10-15.9 (on cord or 1st infant blood gas at < 1 hour of life) WITH b) at least one of the following:
-
An APGAR score ≤5 at 10 minutes OR
-
Prolonged resuscitation (infant receiving IPPV at ≥10 minutes of life) OR
-
An acute perinatal event:
- Abnormal CTG (variable/late foetal HR decelerations)
- Foetal bradycardia
- Prolapsed/ruptured/tight nuchal cord
- Shoulder dystocia
- Uterine rupture
- Maternal haemorrhage/placental abruption
- Maternal trauma (e.g. vehicle accident)
- Mother received CPR
-
Exclusion Criteria:
- Infants < 36 weeks gestation
- No parental/guardian consent
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: CASE_ONLY
- Perspectives temporelles: PROSPECTIVE
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
|---|---|
|
Neonates
Neonates at risk of Neonatal Encephalopathy |
The amplifier is used to acquire and transmit the EEG to the CergenX Wave software that is installed in a COTS computer.
Autres noms:
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
|---|---|
|
Percentage agreement between the CergenX Wave result and stage of NE assigned by modified Sarnat examination (i.e. normal/mild abnormality versus moderate/severe abnormality) between 1-6 hours of life
Délai: From the enrolment and up to 6 hours after birth
|
From the enrolment and up to 6 hours after birth
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in agreement between the modified Sarnat examination and the software-based assessment from the initial assessment (1-6 hours of life) to 24 hours of life (± 6 hours) among infants with initial disagreement.
Délai: From enrolment of the participant and up to 30 hours after birth
|
From enrolment of the participant and up to 30 hours after birth
|
|
|
Level of agreement between modified Sarnat examination, Wave software, and aEEG/cEEG classification at the same time point in infants with available neurophysiologic monitoring.
Délai: From enrolment of the participant and up to 30 hours after birth
|
From enrolment of the participant and up to 30 hours after birth
|
|
|
Association between CergenX Wave software and clinical variables including discharge diagnosis
Délai: From enrolment of the participant and up to 30 hours after birth
|
Discharge diagnoses will be based on the clinical teams ultimate determination, and for analysis will be stratified as perinatal asphyxia without encephalopathy, mild neonatal encephalopathy, moderate encephalopathy, severe encephalopathy or alternate diagnosis. Descriptive statistics will be used to explore the frequency of the output of the Wave device with these diagnoses |
From enrolment of the participant and up to 30 hours after birth
|
|
Assessment of healthcare professional (device users) satisfaction with usability of the device.
Délai: From enrolment of the participant and up to 30 hours after birth
|
An adapted System Usability Scale (SUS) will be used, referred to as a User Experience Questionnaire that utilises a Likert scale. |
From enrolment of the participant and up to 30 hours after birth
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Autres numéros d'identification d'étude
- 25116
- DT 2023 0435 (Autre subvention/numéro de financement: Department of Enterprise, Tourism and Employment. Enterprise Ireland)
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .